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Abstract
Concerns that standard didactic adherence counselling may be inadequate to maximise 
antiretroviral therapy (ART) adherence led us to evaluate more intensive individualised 
motivational adherence counselling. We randomised 297 HIV-positive ART-naïve patients in 
Durban, South Africa, to receive either didactic counselling, prior to ART initiation (n=150), or an 
intensive motivational adherence intervention after initiating ART (n=147). Study arms were 
similar for age (mean 35.8 years), sex (43.1% male), CD4+ cell count (median 121.5 cells/μl) and 
viral load (median 119 000 copies/ml). Virologic suppression at nine months was achieved in 
89.8% of didactic and 87.9% of motivational counselling participants (risk ratio [RR] 0.98, 95% 
confidence interval [CI] 0.90-1.07, p=0.62). 82.9% of didactic and 79.5% of motivational 
counselling participants achieved >95% adherence by pill count at six months (RR 0.96, 95%CI 
0.85-1.09, p=0.51). Participants receiving intensive motivational counselling did not achieve 
higher treatment adherence or virological suppression than those receiving routinely provided 
didactic adherence counselling. These data are reassuring that less resource intensive didactic 
counselling was adequate for excellent treatment outcomes in this setting.
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Introduction
In 2007, at the start of this study, it was estimated that South Africa had 5.7 million human 
immunodeficiency virus (HIV)-infected people (1) with approximately 1700 new infections 
daily (2) highlighting the growing importance of determining the best way to optimise HIV 
treatment. Since the introduction of combination antiretroviral therapy (ART), HIV disease 
has changed from being a predictor of a certain death, to a manageable chronic illness if the 
treatment is taken as prescribed (3, 4). This means ensuring the highest levels of treatment 
adherence, usually at least 95% of medication taken as prescribed (5-7).
Due to the high burden of both tuberculosis (TB) and HIV in South Africa, the development 
of active TB is often the first sign of underlying HIV infection and an important trigger for 
HIV testing and possible ART initiation (8). This was thought to be an efficient patient 
identification strategy at a time when the voluntary HIV testing rate among otherwise 
healthy people was very low (9). There were concerns that integrating HIV and TB 
treatment, with higher pill burden and potential for side effects, might require additional 
adherence support, and require tailored adherence motivation counselling as TB treatment is 
for a defined period of time whereas HIV requires life-long therapy. In the light of this, the 
Centre for the AIDS Programme of Research in South Africa (CAPRISA) established a 
programme of research into integrating TB and HIV treatment and care in 2002 in Durban, 
South Africa.
Interventions to enhance adherence to ART
Early reviews were key in the conceptualisation of the current study. An initial overview of 
published adherence research indicated that adherence was inconsistently measured, and that 
most studies were conducted without control groups which resulted in inconclusive evidence 
(10). A further review of 21 intervention studies up to the end of January 2003, concluded 
that only four studies were randomised controlled trials (RCTs), and that most were 
underpowered but that some studies suggested positive outcomes, which justified additional 
research (11). A research synthesis of 24 intervention trials between 1996 and 2004 (12) 
confirmed that interventions that targeted participants with known adherence problems had a 
larger effect than those that did not.
A major review of RCTs published between 1996 and 2005 identified 19 studies that looked 
at behavioural interventions to enhancing adherence to ART (7). In terms of interventions, 
55% used one-on-one counselling, and 16% used group counselling, mostly delivered by 
health practitioners such as doctors or nurses (47%) and mental health professionals (26%), 
and 53% of the studies used trial staff rather than routine clinical staff. Data from 14 RCTs 
included were analysed assessing the effect of adherence interventions on viral load between 
two weeks and six months post-intervention. It was found that 62% of the intervention arm 
participants controlled their virus, versus 55% of the participants in the control arm. This 
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gives a fairly weak aggregate effect size (OR=1.25, 95%CI 0.99-1.59, N=1247). Although 
the evidence against the null was not conclusive, the percentage of participants in the 
intervention arm that had undetectable viral load versus those in the control arm could 
translate into significant financial and health-systems benefits.
This review also reported 18 trials where the outcome was expressed as effect on adherence 
(the majority of studies measured adherence by self report, between two weeks and six 
months post-intervention), and in this case 62% of participants in the intervention arm and 
50% of participants in the control arm achieved at least 95% adherence (7). This resulted in 
stronger evidence against the null and a stronger aggregated effect size (OR=1.5, 95%CI 
1.16-1.94, N=1633). This larger effect for adherence is not likely to be due to unreliable 
measurement by self-report, as effect sizes were actually larger in studies that used more 
objective measures (e.g. electronic monitoring). Thus, participants in the intervention arm 
were 1.5 times more likely to be 95% or more adherent, and 1.25 times more likely to 
achieve suppressed viral load than participants in the control arm. This effect tended to be 
greater in studies that provided information on ART and interactive discussions regarding 
the cognitions, motivation, and participant expectations. Although it is inherently 
problematic to combine the diverse outcomes from studies with very different interventions 
and designs, this was the first attempt to synthesise the RCT outcome data and it was 
cautiously optimistic about the ability of behavioural interventions to enhance ART and 
strongly in favour of additional, rigorous assessment of adherence interventions by RCT, 
especially in Africa (13).
During the development of the intervention for the current study, we made a site visit to 
Harlem Hospital, and the ‘medication manager’ adherence intervention developed and being 
tested there was observed, and the approach modified and assimilated into the intervention 
being developed for our study (14). The medication manager provided personalised 
adherence support to participants, using a standard assessment protocol to identify and 
address any deficits in adherence information, motivation and behavioural skills. The 
primary endpoint was time to first virologic failure, defined as the first plasma viral load 
above 2000 copies/ml on or after the 4th monthly follow-up visit. In the main intention to 
treat analysis, the medication manager group had 13% lower rate of first virological failure, 
but this was not statistically significant. Participants in the medication manager arm also had 
significantly raised CD4 counts (mean difference of 22.5 cells/μL higher), and better long-
term adherence by self-report. This study provided some evidence that the approach of using 
a theory-based model to identify and correct specific deficits in information, motivation and 
behavioural skills with counselling techniques based on motivational interviewing was 
feasible, and showed promise in enhancing adherence and treatment outcomes on ART.
In summary, the literature indicated that counselling interventions, based on models of 
behaviour change, that provided participant-specific problem-solving and interactive 
sessions, seemed to be most likely to have an effect on improving ART adherence (7, 10, 11, 
15, 16). The motivation, information and behavioural skills model tied to motivational 
interviewing had been used and evaluated in the USA in ART adherence, with some 
preliminary indications that this may be a fruitful avenue for further research (14, 17-19). 
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ART adherence in the context of TB treatment was identified as a key data gap that needed 
to be addressed, as integrated treatment was not the recommended standard of care.
To address our concerns about the adequacy of standard didactic counselling in our setting, 
we conducted a RCT to assess whether intensive individualised motivational adherence 
counselling led to better adherence and treatment outcomes than standard didactic 
counselling in newly diagnosed HIV infected patients initiating antiretroviral therapy.
Methods
Study design and setting
The study was a parallel group (1:1 ratio), open-label randomised controlled trial, with 
concealment of allocation from the person conducting the enrolment. It was conducted at the 
CAPRISA eThekwini HIV-TB clinic, in Durban, South Africa. This research facility adjoins 
to the Prince Cyril Zulu Communicable Diseases Centre, one of the biggest TB outpatient 
treatment clinics in South Africa.
Participants
Between August 2007 to February 2009, we recruited participants 18 years of age or older 
and eligible to initiate ART (at the time, a CD4 T-cell count of 350 or less). The majority of 
these participants were also included in a study of the optimal time to initiate ART in 
patients who were receiving TB treatment (20, 21). Just over 53% of participants were 
receiving TB treatment at the time of their participation in this study, and a further 25.6% 
had completed TB treatment within 4 weeks previous to initiation on ART (described further 
in Table 1 of the results).
ART regimen
The ART regimen used was selected to be compatible with TB treatment (21). The first line 
regimen offered, free of charge, was a once-a-day regimen consisting of enteric-coated 
didanosine (250mg if <60kg, 400mg if >60kg), lamivudine 300mg, and efavirenz 600mg 
(or, nevirapine (200mg twice a day) in the case of pregnancy).
Adherence counselling
TB treatment adherence support was provided separately from the HIV treatment 
programme. This TB treatment service was provided by the Department of Health, 
according to the provincial standard of care, and was not under the control or provision of 
study staff, although completion of the required number of TB drug doses and outcomes of 
TB treatment were assessed as part of the TB and HIV treatment integration studies 
underway at the clinic.
The standard HIV treatment adherence support counselling for this programme was 
delivered by a nongovernmental organisation, consistent with the requirements in the initial 
South African national guidelines for treatment provision for adolescents and adults (22), the 
World Health Organization (WHO) guidelines for scaling up ART in resource-constrained 
settings (23), and with the US Department of Health and Human Services guidelines (24). 
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The counselling focussed on treatment literacy, and was delivered in an educational, or 
didactic, style. The counselling was seen as essential for treatment readiness, and so 
focussed on preparation prior to ART initiation. No formal counselling post-initiation of 
ART was specified, although on-going monitoring of adherence was recommended. We 
were concerned that this approach to adherence support may become less effective over 
time, as counselling group size increased, and the didactic approach might be prone to rote 
repetition of information with inadequate engagement with the individual issues faced by 
patients1.
Procedures
On determination of ART eligibility, all patients received two pre-initiation 20-45 minute 
didactic counselling sessions as standard at the clinic. At the time of the ART initiation visit, 
patients were consented, enrolled and randomised. The randomisation was set up by a 
statistician using a random number generator in SAS, and the randomisation codes contained 
in sequentially numbered, sealed opaque envelopes, stratified in blocks of four or six relative 
to time of TB treatment (described in the baseline characteristics table of the results). The 
didactic arm participants received the final 20-45 minute didactic counselling session only. 
The motivational counselling arm participants instead received the first 30-40 minute 
individualised motivational counselling session, and then the additional four individualised 
motivational counselling sessions at intervals up to six months after initiation of therapy 
(Figure 1). All participants were followed up to at least nine months on treatment. 
Participants still in care had viral load measures taken at 12 months. Adherence was 
assessed by clinic-based pill count at six months post-initiation of therapy.
Content and delivery of the standard didactic counselling—The standard didactic 
counselling consisted of three sessions. The first session covered stigma and discrimination, 
nutrition and taking control of the treatment regimen. The second session focused on HIV 
pathogenesis, routes of infection, HIV testing techniques, and a basic introduction to ART. 
The final session focused on information relating to ART, the drug regimen, the importance 
of adherence, side effects, and the importance of monitoring and the development of 
resistance. Due to the large numbers of participants expected to be enrolled into the 
treatment programme, with increasing pressure to meet the high treatment initiation targets, 
this counselling was designed to be delivered in groups if necessary. Two sessions could be 
provided on the same day, but not all three.
Content and delivery of the individualised motivational counselling—An 
individualised intensive motivational adherence counselling intervention was developed, 
using content based on the information, motivation and behavioural skills model (IMB) of 
adherence to ART (25-27), using counselling delivery techniques from motivational 
interviewing (MI) (28, 29). The counselling was designed to be provided exclusively on a 
one-to-one basis, using a client-centred rather than didactic approach. Counselling could be 
tailored to specific participant needs, promoting an experience that was supportive of 
individualised care.
1We refer to patients in the treatment programme, and to participants when enrolled onto this study.
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MI was developed initially to treat alcohol abuse, and it is amenable to brief counselling 
sessions (30). MI is directive in the sense that the counsellor pursues the goal of examining 
and resolving ambivalence about behaviour change, but also client-centred in that it was 
designed to elicit statements in favour of behaviour change from the clients themselves (29, 
30). A review of trials of MI-based interventions in diverse settings, concluded that this 
approach was more effective than traditional advice giving (31). Although MI was not 
formally used in our study, the motivational counselling did use techniques based on this 
approach. For example, instead of informing participants about potential barriers to 
adherence, and associated solutions, the counsellors encouraged them to think about 
potential barriers to adherence in their own experience and encouraged participants to talk 
about, and opt for, solutions that they felt they could implement in their own lives. As the 
statements about barriers requiring potential behaviour change were made by the 
participants, and the solutions also suggested by them, these counselling sessions were 
expected to be self-motivating. Participants were more likely to take ownership of their 
adherence challenges and successfully enact solutions they had suggested.
According to the IMB model of HIV prevention, initiating and maintaining patterns of HIV 
preventative behaviour depends on individuals being well informed, highly motivated and in 
possession of effective behavioural skills, rather than solely on the possession of knowledge. 
Content for the individualised motivational counselling was identified from this model, 
specifically a version modified for ART adherence (27), a literature review of adherence 
barriers, reasons for non-adherence from our clinic patients, and interviews with adherence 
counsellors and pharmacy staff.
Information was provided on the regimen, correct dosing, identifying and coping with side 
effects, as well as key information on non-adherence and resistance. Personal motivation 
was enhanced through MI-based techniques. Social motivation was encouraged through 
managed disclosure, designed to bring about gradual and safe disclosure over the first six 
months of treatment. Specific behavioural skills were encouraged, including skills to ensure 
clinic visits were kept, integrating dosing into the routine of daily life, and for identifying 
and coping with side effects. Moderating factors like general psychological well being, 
unstable living conditions, and substance or alcohol abuse were address through referrals to 
appropriate services.
The content of the motivational counselling was displayed on table top flipchart folders in 
English and isiZulu, the main local language, with locally relevant imagery like a three 
legged cooking pot to aid understanding and retention, facing the participants. Counselling 
scripts, based on MI techniques, faced the counsellors. The slogans summarised key 
principles like “The Power of Three” (the regimen of three drugs) and “The System of 
Three” (three important strategies for taking the drugs correctly). Additional support 
materials included wall posters for summarising counselling content, symptom solution 
cards that included key slogans and side effect management strategies, ‘prescriptions’ for 
adherence that were participant-agreed commitments to behaviours necessary to adhere 
optimally, as well as a treatment plan card that included pictures of the drugs in the regimen 
and space for a concrete plan for integrating dosing into daily routine. The ‘prescriptions’ 
van Loggerenberg et al. Page 6






















and treatment plan cards were prepared at the first counselling visit, and reviewed and 
amended over the course of the intervention.
Two health educators from the existing nursing staff were trained to administer motivational 
counselling. On the day of treatment initiation participants were counselled on preparing to 
take ART, especially identifying managing side effects, and this was followed up at week 
two with a session on adjusting to ART medications. At two and three months, sessions 
were conducted dealing with on-going treatment issues and managed disclosure. At month 
six, participants were counselled on lifelong therapy concerns.
In accordance with standard clinic practice, and essential to adequate standard of care, once 
initiated on treatment all participants could receive additional ad hoc counselling support, on 
the basis of increasing viral load, decreasing CD4 count, missing doses (either by self-report 
or pill count), or when the participants account of their treatment behaviour did not make 
sense. To provide this, the standard didactic counselling session three was repeated as 
required in both study arms.
Study outcomes
The primary outcome was the proportion of participants with suppressed viral load (plasma 
viral load of <400 copies/ml, HIV-1 RNA-PCR – Roche Diagnostics) at nine months (range 
of eight to 10 months) post-initiation of ART. A secondary outcome looked at adherence by 
pill count over the previous inter-visit period at six months post-initiation of therapy. Pill 
count was expressed as a percentage of the pills taken as prescribed over the study visit 
interval (usually the previous 28 days), by assuming that all non-returned pills had been 
taken over the study visit interval. These data were verified from the clinic records based on 
previous study visit and drugs dispensed by the pharmacy. This measure was recorded at 6 
months, as this was part of the counselling intervention study follow-up. Suppressed viral 
load at 12 months was assessed as an additional secondary outcome.
As early mortality is common in treatment programmes in this region (32, 33), deaths prior 
to three months were not considered as contributing to the primary outcome as they occurred 
too early for treatment adherence to have an impact, and these participants were excluded 
from all analyses. Participants who died after three months, but prior to nine months, were 
considered to have unsuppressed viral load in the analysis.
Sample size and statistical analysis
The individualised motivational counselling was hypothesised to be superior as it was more 
intensive, and provided individually in a client-centred and participatory way. From data 
available during planning, we estimated that we would need at least 150 evaluable outcomes 
in each arm at 9 months, for the study to have 80% power to detect an absolute difference of 
at least 15% in suppressed viral load, estimating 65% suppressed in the didactic counselling 
arm, with a type 1 error of 5%.
As odds ratios exaggerate the magnitude of association for common events (34), and as viral 
load suppression was high in this study, the primary outcome was assessed using risk ratios 
with 95% confidence intervals (CIs). As no adjustment was necessary for the outcomes, no 
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regression model was needed to estimate the risk ratios. All analyses were performed using 
the STATA 11.0 statistical analysis program (College Station, Texas 77845, USA).
Restricted and whole cohort analysis
In the first instance, each analysis was restricted to all participants with outcome data at six, 
nine and 12 months respectively, including those who died after three months who were 
considered to have unsuppressed viral load. To determine the impact of the lost, withdrawn 
from the treatment programme, or relocated participants, and those otherwise with missing 
data, whole cohort analysis was performed where those with no outcome data were assumed 
not to have confirmed suppressed viral load or adherence greater than 95%.
Ethics
This study was approved by the Biomedical Research Ethics committees of the University of 
KwaZulu-Natal, Durban (E326/05), The London School of Hygiene and Tropical Medicine, 
London (5114), and, Columbia University, New York (IRBAAAC0202). The trial was 
registered Clinicaltrials.gov (NCT00408642) on the South African National Health Research 
Ethics Council (NHREC) trials register (DOH-27-0807-2004).
Results
297 ART naïve patients were eligible and all consented to be enrolled, 150 randomised to 
the didactic and 147 in the individualised motivational counselling arm (Figure 2). All 
participants were followed up and analysed in the arms into which they were randomised. 
Baseline demographic and clinical characteristics were similar in both groups (Table 1).
Follow-up to nine months
Ten (3.4%) of the 297 participants died prior to three months and were excluded from all 
outcome analyses (Figure 2). Of the remaining 287, eight (2.7%) were lost to follow-up, 
three (1.0%) had withdrawn from the treatment programme, six (2.0%) had defaulted 
treatment, seven (2.4%) were known to have relocated and 11 (3.7%) were missing viral 
loads or had missed their visit. 250 (84.2%) had viral load measures, and two (0.7%) had 
died between three and nine months. 229 (77.1%) participants, 117 in the didactic and 112 
in the motivational counselling arm, had recorded adherence measures at 6 months.
Intervention coverage
All participants in the didactic counselling arm had to have documented evidence of having 
completed the standard adherence support programme as this was a requirement prior to 
initiation on ART. Of the 131 participants from the individualised motivational counselling 
arm in follow-up for at least six months and, therefore, expected to have completed five 
sessions, 97.7% (128/131) completed at least three and 88.5% (116/131) completed all five 
sessions.
Ad hoc counselling support
During the course of the study there were 101 recorded instances of ad hoc adherence 
counselling for 49 study participants. 71 of these instances occurred in the 31 didactic 
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counselling participants, versus only 30 sessions in 18 of the motivational counselling 
participants (Mann-Whitney p=0.04). One participant in the didactic counselling arm 
accounted for five of these sessions, and another for eight.
Reasons for repeat adherence counselling referral were captured in 99 of cases (Table 2). 
The most frequent reason given for referring a participant for ad hoc counselling was that 
the incorrect number of pills was returned at the study visit, slightly more frequent in the 
didactic counselling arm. Participants in the didactic counselling arm were also more than 
twice as likely to have been referred for poor knowledge of drug dosing instructions. 
However, there is no evidence that reasons for referral differed by counselling type (Fisher's 
exact p = 0.89).
Primary outcome: Suppressed viral load at nine months
A total of 252 participants were included in the restricted analysis; 250 with viral load 
measures at nine months, and two participants (one in each arm) who died between three 
and nine months. By nine months, suppressed viral load was achieved in 89.8% (115/128) of 
the participants in the didactic counselling arm and in 87.9% (109/124) of participants in the 
motivational counselling arm (RR=0.98; 95%CI 0.90-1.07, p=0.62)(Table 3). In the whole 
cohort analysis, suppressed viral load was achieved in 78.8% (115/146) of the participants in 
the didactic, and in 77.3% (109/141) of the motivational counselling arm (RR=0.98; 95%CI 
0.87-1.11, p=0.76).
In predetermined exploratory analysis (not shown here), adjustment for gender, age, 
employment status, education level, relationship status, point of HIV treatment initiation in 
relation to TB treatment, viral load and CD4 count by log binomial regression (35) had no 
major impact on the primary outcome of the trial.
Secondary outcome 1: >95% adherence by pill count at six months
In the restricted analysis, 82.9% (97/117) of those in the didactic and 79.5% (89/112) of the 
individualised motivational counselling arm participants had a pill count greater than 95% 
(RR = 0.96; 95%CI 0.85-1.09, p=0.51). In the whole cohort analysis, 66.4% (97/146) in the 
didactic arm versus 63.1% (89/141) of those in motivational arm had adherence >95% (RR 
= 0.95; 95%CI 0.80-1.13, p=0.56).
Secondary outcome 2: Suppressed viraemia at 12 months
As part of clinical follow-up of all retained participants, viral load data were available for 
247 participants at 12 months post-initiation of therapy. Of those who provided data, 91.1% 
(112/123) in the didactic and 87.9% (109/124) in the motivational counselling arm had 
suppressed viral load (RR = 0.97; 95% CI 0.89-1.05, p=0.42). In the whole cohort analysis, 
76.7% (112/146) in the didactic versus 77.3% (109/141) in the motivational arm had 
suppressed viral load (RR = 1.0; 95% CI 0.89-1.14, p=0.91).
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In our trial, ART-naïve participants who received intensive individualised motivational 
counselling did not have improved viral suppression or adherence outcomes. Exposure to the 
motivational counselling was high, and poor coverage was not likely to be a factor. Viral 
suppression was high in both groups. While the 252 participants with treatment outcome at 9 
months assessed in the restricted analysis was below the target of 300 evaluable participants, 
the whole cohort analysis of all 297 participants did not lead to materially different trial 
outcomes.
Treatment outcome data from the southern Africa region at the time of this study help to 
contextualise the results (Table 4). These data, mostly from other well-resourced treatment 
trials, seem to also show good outcomes. However, significant losses to follow up and early 
mortality are masked as most results are given for ‘on treatment’ participants. Where an 
intention to treat estimate is given, the result is much poorer (36), highlighting the good 
outcome in our current study. Including data from other southern African countries, which 
also includes real-world clinic data, indicate much lower estimates, especially in adolescent 
patients (37). One study from a rural setting in KwaZulu-Natal indicates that suppression 
rates have increased significantly from 2005, to 2007, most probably due to improved 
service provision and patient tracking procedures (38).
Factors other than the counselling are likely to have contributed to the good outcomes 
observed in the current study. It is possible that the repeated adherence assessments 
functioned as an adherence intervention in both arms by reminding participants of the 
importance of adherence. The tracking and tracing in place at the clinic required for trial 
follow-up reduced the likelihood of missed study visits and losses to follow-up. Tracking is 
key as it is a reminder for visits, ensures good refill rates, and also communicates to each 
participant that they are important. In this setting where access to treatment is difficult, the 
threat of losing access to treatment may have exerted a powerful motivational influence, as 
would direct experiences of morbidity and mortality in the community.
The clinic also provides a selection of other supportive activities, not formally considered to 
be part of the standard of care at the start of the study, but would have improved outcomes 
beyond what would be expected with didactic counselling alone. These include pillboxes to 
aid remembering to take pills, pill packet illustrations for illiterate participants and dosing 
instructions provided in the local language. Ad hoc counselling was provided to any 
participants who had clinical problems or adherence measures that concerned staff, as 
previously indicated. These sessions were significantly more likely to occur in the didactic 
counselling arm participants, which is not surprising as the motivational counselling 
participants were more likely to be scheduled for an individualised counselling session 
within which they would have dealt with any issues relating to poor adherence. Although it 
is possible that the ad hoc counselling meant that the control arm might be biased towards 
the null, this ad hoc counselling was part of the standard of care against which the 
intervention counselling would need to be an improvement, and so this was not unexpected, 
or avoidable. In addition to this, these sessions were only conducted in a relatively small 
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number of cases and participants, and the content remained didactic rather than 
motivational.
All of these factors are implementable in other settings, and would be amenable to study as 
adherence interventions in their own right. It is also possible that once the Hawthorne effect 
of being intensively followed up in this study wore off (39), that differences between the 
adherence strategies between the two arms might, over time, lead to greater sustained 
adherence and viral suppression in one of the arms, but this was not feasible to assess within 
the time frames of the current study.
Finally, the majority of participants were co-enrolled on a TB/HIV treatment study or were 
previous TB treatment patients. They remained a selected group of participants who had 
experience of, and likely success with, TB treatment adherence. It was considered probable 
during the conceptualisation of this trial that the burden of concurrent or sequential TB 
treatment and ART would negatively impact on treatment adherence. That the participants in 
this study have done so well is very promising in relation to the increased calls to integrate 
HIV and TB treatment, and the very large proportion of HIV patients this specific 
population represents in South Africa. These results support closer integration of HIV and 
TB treatment.
Major strengths of our study include the randomised controlled trial design, use of a theory-
based intervention, the use of viral load as the primary outcome, and the trial setting of a TB 
clinic, which is a common entry point for HIV treatment in Africa. While adherence 
intervention studies report adherence and treatment outcomes for relatively short periods of 
time, often only for up to immediately after the completion of the intervention being tested 
(7, 40), this study assessed treatment outcomes up to 12 months post-initiation of treatment.
A limitation of this trial was that the high viral suppression rate following standard didactic 
counselling was not anticipated, the sample size calculation assumed only 65% suppression 
in the didactic arm, and the study was not powered for small incremental benefits of 
motivational counselling since substantial benefits would be needed from this intensive and 
more costly approach to warrant its implementation. A further limitation is that the setting of 
this trial in a TB clinic may reduce its generalizability.
Although this study showed that it is feasible to roll out this more intensive individualised 
motivational counselling in a resource-constrained setting, the counselling was designed to 
target issues with specific skills deficits at the individual level that may not have been 
appropriate for this setting. This intensive individualised motivational counselling approach 
is more likely to be necessary and effective where barriers to adherence are personal and 
motivational rather than structural, and in populations who experience many of these 
barriers. Identification of a population at high risk for non-adherence, or of participants who 
are experiencing difficulties, may be a more appropriate target for testing this intervention. 
This is likely to be even more important now that treatment provision has expanded so much 
outside of clinical research settings.
In summary, we conclude that the standard of care didactic counselling was adequate in the 
setting of our TB clinic, and that intensive personalised one-on-one motivational counselling 
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did not significantly improve adherence and treatment outcomes in this study. The finding 
that motivational counselling had no benefit over traditional didactic counselling in this 
setting is an important contribution to the literature on HIV treatment adherence counselling, 
as it does warn against implementing intensive individualised motivational counselling in 
settings where less resource intensive didactic counselling may be adequate. These study 
results empower health educators, nurses or community health workers to provide 
efficacious adherence support in a limited and structured counselling intervention.
Acknowledgements
This research was supported by the Doris Duke Charitable Foundation-funded Operations Research on AIDS Care 
and Treatment in Africa (ORACTA) Programme (Grant # 2005058). The Association of Commonwealth 
Universities funded PhD study for Francois van Loggerenberg at London School of Hygiene and Tropical 
Medicine. He was also supported by the Columbia University-Southern African Fogarty AIDS International 
Training and Research Programme (AITRP) funded by the Fogarty International Center, National Institutes of 
Health (grant #D43TW00231). The National Institute of Allergy and infectious Disease (NIAID), National 
Institutes of Health (NIH) (grant# AI51794) funded the infrastructure for this research. Alison Grant was supported 
by a Public Health Career Scientist award from the UK Department of Health. We would like to thank the clinic 
research support staff who provided the data collection, nursing services, as well as the administrative and 
counselling support for CAPRISA 058 study, Senzo Hlathi, Goodness Gumede, and Thandi Shezi. Dr Leila 
Mansoor provided advice and assisted with the training of the clinic counselling staff. Lise Werner, Anneke Grobler 
and Nonhlanhla Yende provided additional statistical guidance and support. Jayraj Ramota was the data manager, 
and data were entered and validated by Mfanafuthi Mthambela. Clive Govender provided data quality control. 
Members of the Center for Health, Intervention, and Prevention (CHIP), University of Connecticut, who developed 
the IMB model, were very helpful in the conceptualisation, conduct and analysis of this trial. Specifically, Paul 
Shuper and K. Rivet Amico provided on-going support and guidance. Katherine Fielding and Simon Lewin 
provided support as members of the PhD advisory committee. The intervention was based on one developed by 
Gerald Friedland (Yale University, USA), Marita Murrman, Patricia Torro, and Wafaa El-Sadr (all Columbia 
University, USA) in earlier work, and was generously shared; their support and guidance during the 
conceptualisation of this study conducted is acknowledged. We would like to especially acknowledge the 
participants who took part in this study.
References
1. UNAIDS. AIDS epidemic update : November 2009. WHO; Geneva, Switzerland: 2009. 
2. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, Regensberg L, et al. Adherence to highly 
active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South 
African adults. J Acquir Immune Defic Syndr. 2006; 43(1):78–84. [PubMed: 16878045] 
3. Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. 
Antiviral Res. 2010; 85(1):1–18. [PubMed: 20018391] 
4. Jones R, Gazzard B. The cost of antiretroviral drugs and influence on prescribing policies. Int J STD 
AIDS. 2006; 17(8):499–506. [PubMed: 16925892] 
5. Orrell C. Antiretroviral adherence in a resource-poor setting. Curr HIV/AIDS Rep. 2005; 2(4):171–
6. [PubMed: 16343374] 
6. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease 
inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000; 133(1):21–
30. [PubMed: 10877736] 
7. Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N. Efficacy of interventions in improving 
highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of 
randomized controlled trials. J Acquir Immune Defic Syndr. 2006; 43(Suppl 1):S23–35. [PubMed: 
17133201] 
8. Abdool Karim SS, Abdool Karim Q, Friedland G, Lalloo U, El-Sadr WM. Implementing 
antiretroviral therapy in resource-constrained settings: opportunities and challenges in integrating 
HIV and tuberculosis care. AIDS. 2004; 18(7):975–9. [PubMed: 15096799] 
van Loggerenberg et al. Page 12






















9. Nelson Mandela/HSRC Study of HIV/AIDS. South African national HIV prevalence, behavioural 
risks and mass media.. In: Shisana, O.; Simbayi, L., editors. Household survey 2002. Human 
Sciences Research Council; Cape Town: 2002. 
10. Ammassari A, Trotta MP, Murri R, Castelli F, Narciso P, Noto P, et al. Correlates and predictors of 
adherence to highly active antiretroviral therapy: overview of published literature. J Acquir 
Immune Defic Syndr. 2002; 31(Suppl 3):S123–7. [PubMed: 12562034] 
11. Simoni JM, Frick PA, Pantalone DW, Turner BJ. Antiretroviral adherence interventions: a review 
of current literature and ongoing studies. Top HIV Med. 2003; 11(6):185–98. [PubMed: 
14724327] 
12. Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a 
research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr. 2006; 41(3):285–97. 
[PubMed: 16540929] 
13. Gordon CM. Commentary on Meta-Analysis of Randomized Controlled Trials for HIV Treatment 
Adherence Interventions: Research Directions and Implications for Practice. J Acquir Immune 
Defic Syndr. 2006; 43(Suppl 1):S36–S40. [PubMed: 17133203] 
14. Mannheimer SB, Morse E, Matts JP, Andrews L, Child C, Schmetter B, et al. Sustained Benefit 
From a Long-Term Antiretroviral Adherence Intervention: Results of a Large Randomized 
Clinical Trial. J Acquir Immune Defic Syndr. 2006; 43(Suppl 1):S41–S7. [PubMed: 17091022] 
15. Cote JK, Godin G. Efficacy of interventions in improving adherence to antiretroviral therapy. Int J 
STD AIDS. 2005; 16(5):335–43. [PubMed: 15949060] 
16. Simoni JM, Amico KR, Pearson CR, Malow R. Strategies for promoting adherence to 
antiretroviral therapy: a review of the literature. Curr Infect Dis Rep. 2008; 10(6):515–21. 
[PubMed: 18945394] 
17. DiIorio C, McCarty F, Resnicow K, McDonnell Holstad M, Soet J, Yeager K, et al. Using 
motivational interviewing to promote adherence to antiretroviral medications: a randomized 
controlled study. AIDS Care. 2008; 20(3):273–83. [PubMed: 18351473] 
18. Davies G, Koenig LJ, Stratford D, Palmore M, Bush T, Golde M, et al. Overview and 
implementation of an intervention to prevent adherence failure among HIV-infected adults 
initiating antiretroviral therapy: lessons learned from Project HEART. AIDS Care. 2006; 18(8):
895–903. [PubMed: 17012078] 
19. Koenig LJ, Pals SL, Bush T, Pratt Palmore M, Stratford D, Ellerbrock TV. Randomized controlled 
trial of an intervention to prevent adherence failure among HIV-infected patients initiating 
antiretroviral therapy. Health Psychol. 2008; 27(2):159–69. [PubMed: 18377134] 
20. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of 
initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010; 362(8):697–706. 
[PubMed: 20181971] 
21. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, et al. Integration of 
antiretroviral therapy with tuberculosis treatment. The New England journal of medicine. 2011; 
365(16):1492–501. [PubMed: 22010915] 
22. Department of Health. National Antiretroviral Treatment Guideliness. Pretoria: National 
Department of Health. 2004
23. WHO. Scaling up antiretroviral therapy in resource-limited settings: Treatment guidelines for a 
public health approach (2003 revision). World Health Organization; Geneva: 2004. 
24. DHHS. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 
Washington. :2004.
25. Fisher J, Fisher W, Bryan A, Misovich S. Information-Motivation-Behavioural skills model-based 
HIV risk behaviour change interventions for inner city high school youth. Health Psychology. 
2002; 21(2):177–86. [PubMed: 11950108] 
26. Fisher, JD.; Fisher, WA. The Information-Motivation-Behavioural Skills Model.. In: DiClemente, 
RJ.; Crosby, RA.; Kegler, MC., editors. Emerging Theories in Health Promotion Practice and 
Research. Jossey-Bass; San Francisco, CA: 2002. p. 40-70.
27. Fisher JD, Fisher WA, Amico KR, Harman JJ. An information-motivation-behavioral skills model 
of adherence to antiretroviral therapy. Health Psychol. 2006; 25(4):462–73. [PubMed: 16846321] 
van Loggerenberg et al. Page 13






















28. Fisher JD, Fisher WA, Cornman DH, Amico RK, Bryan A, Friedland GH. Clinician-delivered 
intervention during routine clinical care reduces unprotected sexual behavior among HIV-infected 
patients. J Acquir Immune Defic Syndr. 2006; 41(1):44–52. [PubMed: 16340472] 
29. Rollnick S, Butler CC, McCambridge J, Kinnersley P, Elwyn G, Resnicow K. Consultations about 
changing behaviour. BMJ. 2005; 331(7522):961–3. [PubMed: 16239696] 
30. Emmons KM, Rollnick S. Motivational interviewing in health care settings. Opportunities and 
limitations. Am J Prev Med. 2001; 20(1):68–74. [PubMed: 11137778] 
31. Rubak S, Sandbaek A, Lauritzen T, Christensen B. Motivational interviewing: a systematic review 
and meta-analysis. Br J Gen Pract. 2005; 55(513):305–12. [PubMed: 15826439] 
32. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing 
antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008; 22(15):1897–908. 
[PubMed: 18784453] 
33. Lawn SD, Little F, Bekker LG, Kaplan R, Campbel E, Orrell C, et al. Changing mortality risk 
associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS. 2009; 23(3):
335–42. [PubMed: 19114870] 
34. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies 
of common outcomes. JAMA. 1998; 280(19):1690–1. [PubMed: 9832001] 
35. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J 
Epidemiol. 2004; 159(7):702–6. [PubMed: 15033648] 
36. Barth RE, van der Meer JT, Hoepelman AI, Schrooders PA, van de Vijver DA, Geelen SP, et al. 
Effectiveness of highly active antiretroviral therapy administered by general practitioners in rural 
South Africa. Eur J Clin Microbiol Infect Dis. 2008; 27(10):977–84. [PubMed: 18629557] 
37. Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, Regensberg L, et al. Antiretroviral 
therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in 
southern Africa. Journal of acquired immune deficiency syndromes. 2009; 51(1):65–71. [PubMed: 
19282780] 
38. Mutevedzi PC, Lessells RJ, Heller T, Barnighausen T, Cooke GS, Newell ML. Scale-up of a 
decentralized HIV treatment programme in rural KwaZulu-Natal, South Africa: does rapid 
expansion affect patient outcomes? Bull World Health Organ. 2010; 88(8):593–600. [PubMed: 
20680124] 
39. McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P. The Hawthorne Effect: a 
randomised, controlled trial. BMC Med Res Methodol. 2007; 7:30. [PubMed: 17608932] 
40. Simoni JM, Amico KR, Smith L, Nelson K. Antiretroviral adherence interventions: translating 
research findings to the real world clinic. Curr HIV/AIDS Rep. 2010; 7(1):44–51. [PubMed: 
20425057] 
van Loggerenberg et al. Page 14























Study schema; a parallel group RCT, ‘open label’/unblinded, with concealment of allocation 
from the person enrolling participants, and random assignment.
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Participant enrolment and disposition at 9 months
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Table 1
Characteristics and clinical features at time of enrolment, overall and by counselling arm
Baseline factors Overall (n=297) Didactic counselling (n=150) Motivational counselling (n=147)
Age, years (mean, SD
~
)














Male n (%) 128 (43.1%) 64 (42.7%) 64 (43.5%)










Baseline viral load copies/mL (median, 
IQR)
119 000 (27 650 – 
433 500)
n=280
135 853.5 (44 600 – 353 000)
n=142
102 527 (16 600 – 521 000)
n=138
Marital status:
Single 266 (89.6%) 137 (91.3%) 129 (87.8%)
Married 22 (7.4%) 8 (5.3%) 14 (9.5%)
Widowed 9 (3.0%) 5 (3.3%) 4 (2.7%)
Education:
Primary school and less 37 (12.7%) 20 (13.5%) 17 (11.8%)
Secondary school, not complete 135 (46.2%) 75 (50.7%) 60 (41.7%)


















Early (within 4 weeks of starting TB 
treatment)
88 (29.6%) 44 (29.3%) 44 (30.0%)
Post-intensive TB (within 4 weeks of 
completing the intensive phase)
70 (23.6%) 33 (22.0%) 37 (25.1%)
Post-maintenance TB (within 4 weeks of 
completing TB treatment)
76 (25.6%) 39 (26.0%) 37 (25.1%)
Other (not specifically related to TB 
treatment)
63 (21.2%) 34 (22.7%) 29 (19.7%)
~
SD = standard deviation, IQR = interquartile range
#
One participant was enrolled on the basis of self-reported age of 18, but was younger on confirmation. Ethics committee approved inclusion of 
data from this participant in the study.
*
Numbers only shown when less than the column total. Data were extracted from participant clinic files and were not available for all participants
%
This refers to the timing of ART relative to TB treatment; 21.2% of participants did not currently have TB, or did not have a record of recently 
completed TB treatment






















van Loggerenberg et al. Page 18
Table 2
Reasons given for referral to ad hoc counselling, overall and by study arm
Arm: Overall (n=99) Didactic counselling (n=69) Motivational counselling (n=30)
Incorrect number of doses returned 45 (45.5%) 33 (47.8%) 12 (40%)
Missed Clinic visits 21 (21.2%) 14 (20.3%) 7 (23.3%)
Self-reported missed doses 8 (8.1%) 5 (7.3%) 3 (10%)
Multiple reasons 8 (8.1%) 6 (8.7%) 2 (6.7%)
No doses returned 6 (6.1%) 3 (4.4%) 3 (10.0%)
Poor knowledge of drug dosing 6 (6.1%) 5 (7.3%) 1 (3.3%)
Treatment failure/drug resistance 2 (2.0%) 1 (1.5%) 1 (3.3%)
Other 3 (3.0%) 2 (2.9%) 1 (3.3%)
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Table 3
Viral load and adherence outcomes for the study, restricted and whole cohort analyses






% suppressed viral load at 9 months Restricted 89.8% (115/128) 87.9% (109/124) 0.98 (0.90-1.07) 0.62
Whole cohort 78.8% (115/146) 77.3% (109/141) 0.98 (0.87-1.11) 0.76
Secondary outcomes
% suppressed viral load at 12 months Restricted 91.1% (112/123) 87.9% (109/124) 0.97 (0.89-1.05) 0.42
Whole cohort 76.7% (112/146) 77.3% (109/141) 1.0 (0.89-1.14) 0.91
% >95% adherence by pill count at 6 
months
Restricted 82.9% (97/117) 79.5% (89/112) 0.96 (0.85-1.09) 0.51
Whole cohort 66.4% (97/146) 63.1% (89/141) 0.95 (0.80-1.13) 0.56
*
Confidence Interval
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Table 4
Treatment outcomes in southern Africa, including the current study, showing percentage with suppressed viral 
load
Study Country N ARV Access, programme 
type
% VL <400 copies/ml
Orrell et al., 200330 South Africa 289 Free cART, clinical trials, no 
formal adherence intervention.
12 months: 70.9%




34 (of 287 at 
baseline)
Free cART.
Observational cohort, intensive 
adherence support with 
treatment supporters.







Michaels, 200532 South Africa 110 Free cART, observational 
cohort.
12 months: 89.0%




Service fee, observational 
cohort.
12 months: 83.0% (on treatment)
12 months: 55.0% (whole cohort)
12 months: 71.0% (on treatment)
12 months: 53.0% (whole cohort)

















Update on Coetzee et al., 2004.
12 months: 87.6%
24 months: 86.7%
Mutevedzi et al., 
201028
South Africa 3010 Rural KwaZulu-Natal, 
decentralised in public health 
clinics, free cART. 3 year 
observational cohort.
12 months: 76.7% (overall)
12 months: 78.5% (Sep. 07)




Current study South Africa 297 Urban KwaZulu-Natal, free 
cART in RCT
9 months (whole cohort):
Control: 78.8%
Intervention: 77.3%




Study has more stringent <25 copies/ml level for viral load suppression
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